Atyr Pharma Inc (ATYR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -49,054 | -31,793 | -15,487 | -50,397 | -35,636 |
| Depreciation Amortization | -614 | -393 | -41 | -430 | 56 |
| Other Working Capital | -8,538 | -12,110 | -7,592 | 15,012 | 11,493 |
| Other Operating Activity | 2,219 | 1,467 | 740 | 2,594 | 1,928 |
| Operating Cash Flow | $-55,987 | $-42,829 | $-22,380 | $-33,221 | $-22,159 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 23,358 | 5,397 | -1,339 | -15,927 | -33,762 |
| PPE Investments | -40 | -25 | -17 | -4,200 | -4,183 |
| Investing Cash Flow | $23,318 | $5,372 | $-1,356 | $-20,127 | $-37,945 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -369 | -244 | -121 | -394 | -279 |
| Common Stock Issued | 21,394 | 21,374 | 7,851 | 66,624 | 60,475 |
| Financing Cash Flow | $21,025 | $21,130 | $7,730 | $66,230 | $60,196 |
| Beginning Cash Position | 26,028 | 26,028 | 26,028 | 13,146 | 13,146 |
| End Cash Position | 14,384 | 9,701 | 10,022 | 26,028 | 13,238 |
| Net Cash Flow | $-11,644 | $-16,327 | $-16,006 | $12,882 | $92 |
| Free Cash Flow | |||||
| Operating Cash Flow | -55,987 | -42,829 | -22,380 | -33,221 | -22,159 |
| Capital Expenditure | -40 | -25 | -17 | -4,215 | -4,198 |
| Free Cash Flow | -56,027 | -42,854 | -22,397 | -37,436 | -26,357 |